Long-Term Lipid Profile Changes After Roux-en-Y Gastric Bypass Surgery
Overview
This prospective observational study of 314 patients followed for over 10 years after Roux-en-Y gastric bypass (RYGB) demonstrates sustained improvements in lipid profiles, including reductions in LDL cholesterol and triglycerides and increases in HDL cholesterol. The study also explores associations between lipid changes and weight loss as well as baseline demographic and clinical parameters.
Background
Obesity and overweight are major risk factors for cardiovascular disease (CVD) and related conditions such as dyslipidemia, type II diabetes, and hypertension. Dyslipidemia, characterized by elevated triglycerides and LDL cholesterol and low HDL cholesterol, independently increases CVD risk. Bariatric surgeries like RYGB are effective treatments for severe obesity and have been shown to improve lipid profiles and reduce cardiovascular risk. However, most studies have follow-up periods of up to 5 years, with limited data on lipid changes beyond 10 years post-surgery.
Data Highlights
Parameter
Timepoint
Measurement
LDL cholesterol
Baseline and 1-2 years
Calculated using Friedewald formula
Triglycerides
Baseline and follow-ups
Measured fasting venous blood
HDL cholesterol
Baseline and follow-ups
Measured fasting venous blood
Weight and BMI
Baseline, 1-2, 5, and 10 years
Measured and % total weight loss calculated
Sample size
Baseline
314 patients included after exclusions
Key Findings
RYGB surgery leads to significant and sustained improvements in lipid profiles over more than 10 years.
LDL cholesterol and triglyceride levels decreased, while HDL cholesterol levels increased postoperatively.
Changes in lipid parameters correlated with weight loss metrics such as percent total weight loss (%TWL).
The proportion of patients exceeding guideline thresholds for LDL, triglycerides, and HDL decreased at long-term follow-up.
Pharmaceutical treatment for hyperlipidemia remained stable, indicating lipid improvements were largely attributable to surgery and weight loss.
Baseline demographic and clinical parameters influenced the degree of lipid profile improvement.
Clinical Implications
Clinicians can expect durable improvements in lipid profiles following RYGB, contributing to reduced cardiovascular risk in patients with severe obesity. Monitoring lipid parameters alongside weight loss metrics is important for long-term management. Stable use of lipid-lowering medications suggests surgery-induced metabolic changes play a key role in sustained lipid improvements.
Conclusion
This study confirms that RYGB produces long-lasting beneficial effects on lipid profiles, with improvements maintained beyond 10 years post-surgery. These findings support the role of bariatric surgery as an effective intervention for dyslipidemia in severe obesity.
References
BAROBS Study Group 2024 -- Long-Term Lipid Profile Alterations Following Roux-en-Y Gastric Bypass
